Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 227

1.

Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.

Rodriguez-Freixinos V, Lheureux S, Mandilaras V, Clarke B, Dhani NC, Mackay H, Butler MO, Wang L, Siu LL, Kamel-Reid S, Stockley T, Bedard PL, Oza AM.

Gynecol Oncol. 2019 Feb 18. pii: S0090-8258(19)30108-8. doi: 10.1016/j.ygyno.2019.02.005. [Epub ahead of print]

PMID:
30792002
2.

Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.

Tomasini P, Mascaux C, Jao K, Labbe C, Kamel-Reid S, Stockley T, Hwang DM, Leighl NB, Liu G, Bradbury PA, Pintilie M, Tsao MS, Shepherd FA.

Clin Lung Cancer. 2018 Dec 19. pii: S1525-7304(18)30333-4. doi: 10.1016/j.cllc.2018.12.009. [Epub ahead of print]

PMID:
30770327
3.

Somatic Tumor Variant Filtration Strategies to Optimize Tumor-Only Molecular Profiling Using Targeted Next-Generation Sequencing Panels.

Sukhai MA, Misyura M, Thomas M, Garg S, Zhang T, Stickle N, Virtanen C, Bedard PL, Siu LL, Smets T, Thijs G, Van Vooren S, Kamel-Reid S, Stockley TL.

J Mol Diagn. 2019 Mar;21(2):261-273. doi: 10.1016/j.jmoldx.2018.09.008. Epub 2018 Dec 19.

PMID:
30576869
4.

Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation.

McCarthy AJ, Capo-Chichi JM, Spence T, Grenier S, Stockley T, Kamel-Reid S, Serra S, Sabatini P, Chetty R.

J Pathol Clin Res. 2018 Nov 1. doi: 10.1002/cjp2.120. [Epub ahead of print]

5.

Proficiency Testing of Standardized Samples Shows Very High Interlaboratory Agreement for Clinical Next-Generation Sequencing-Based Oncology Assays.

Merker JD, Devereaux K, Iafrate AJ, Kamel-Reid S, Kim AS, Moncur JT, Montgomery SB, Nagarajan R, Portier BP, Routbort MJ, Smail C, Surrey LF, Vasalos P, Lazar AJ, Lindeman NI.

Arch Pathol Lab Med. 2018 Oct 30. doi: 10.5858/arpa.2018-0336-CP. [Epub ahead of print]

PMID:
30376374
6.

The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes.

McNamara CJ, Panzarella T, Kennedy JA, Arruda A, Claudio JO, Daher-Reyes G, Ho J, Siddiq N, Devlin R, Tsui H, Su J, Stockley T, Sukhai M, Kanwar N, Chan S, Maze D, Schimmer A, Schuh A, Sibai H, Viswabandya A, Yee K, Minden MD, Kamel-Reid S, Gupta V.

Blood Adv. 2018 Oct 23;2(20):2658-2671. doi: 10.1182/bloodadvances.2018021469.

7.

Distinct patterns of clonal evolution in patients with concurrent myelo- and lymphoproliferative neoplasms.

Kennedy JA, Medeiros JJF, Dobson SM, Arruda A, Sukhai MA, Stockley T, Tierens A, Minden MD, Kamel-Reid S, Dick JE, Gupta V.

Blood. 2018 Nov 15;132(20):2201-2205. doi: 10.1182/blood-2018-04-845065. Epub 2018 Sep 24. No abstract available.

PMID:
30249785
8.

Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy.

Berlin A, Murgic J, Hosni A, Pintilie M, Salcedo A, Fraser M, Kamel-Reid S, Zhang J, Wang Q, Ch'ng C, Deheshi S, Davicioni E, van der Kwast T, Boutros PC, Bristow RG, Chua MLK.

Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):84-91. doi: 10.1016/j.ijrobp.2018.08.030. Epub 2018 Aug 29.

9.

Additional germline findings from a tumor profiling program.

Stjepanovic N, Stockley TL, Bedard PL, McCuaig JM, Aronson M, Holter S, Semotiuk K, Leighl NB, Jang R, Krzyzanowska MK, Oza AM, Gupta A, Elser C, Ahmed L, Wang L, Kamel-Reid S, Siu LL, Kim RH.

BMC Med Genomics. 2018 Aug 9;11(1):65. doi: 10.1186/s12920-018-0383-5.

10.

The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.

Jao K, Tomasini P, Kamel-Reid S, Korpanty GJ, Mascaux C, Sakashita S, Labbé C, Leighl NB, Liu G, Feld R, Bradbury PA, Hwang DM, Pintilie M, Tsao MS, Shepherd FA.

Lung Cancer. 2018 Sep;123:22-29. doi: 10.1016/j.lungcan.2018.06.023. Epub 2018 Jun 19.

PMID:
30089591
11.

Lung cancer in never smokers from the Princess Margaret Cancer Centre.

Korpanty GJ, Kamel-Reid S, Pintilie M, Hwang DM, Zer A, Liu G, Leighl NB, Feld R, Siu LL, Bedard PL, Tsao MS, Shepherd FA.

Oncotarget. 2018 Apr 27;9(32):22559-22570. doi: 10.18632/oncotarget.25176. eCollection 2018 Apr 27.

12.

Evidence-based best practices for EGFR T790M testing in lung cancer in Canada.

Stockley T, Souza CA, Cheema PK, Melosky B, Kamel-Reid S, Tsao MS, Spatz A, Karsan A.

Curr Oncol. 2018 Apr;25(2):163-169. doi: 10.3747/co.25.4044. Epub 2018 Apr 30.

13.

Translation of Knowledge to Practice-Improving Awareness in NSCLC Molecular Testing.

Zer A, Cutz JC, Sekhon H, Hwang DM, Sit C, Maganti M, Sung M, Binnie M, Brade A, Chung TB, Kamel-Reid S, Paul N, Tsao MS, Waddell T, da Cunha Santos G, Patel M, Carter RF, Leighl NB.

J Thorac Oncol. 2018 Jul;13(7):1004-1011. doi: 10.1016/j.jtho.2018.03.005. Epub 2018 Mar 11.

PMID:
29535011
14.

AML refractory to primary induction with Ida-FLAG has a poor clinical outcome.

Kavanagh S, Heath E, Hurren R, Gronda M, Barghout SH, Liyanage SU, Siriwardena TP, Claudio J, Zhang T, Sukhai M, Stockley TL, Kamel-Reid S, Rostom A, Lutynski A, Khalaf D, Rydlewski A, Chan SM, Gupta V, Maze D, Sibai H, Schuh AC, Yee K, Minden MD, Schimmer AD.

Leuk Res. 2018 May;68:22-28. doi: 10.1016/j.leukres.2018.02.012. Epub 2018 Feb 20.

PMID:
29518628
15.

Standardizing biomarker testing for Canadian patients with advanced lung cancer.

Melosky B, Blais N, Cheema P, Couture C, Juergens R, Kamel-Reid S, Tsao MS, Wheatley-Price P, Xu Z, Ionescu DN.

Curr Oncol. 2018 Feb;25(1):73-82. doi: 10.3747/co.25.3867. Epub 2018 Feb 28.

16.

Prognostic Significance of Human Papilloma Virus and p16 Expression in Patients with Vulvar Squamous Cell Carcinoma who Received Radiotherapy.

Yap ML, Allo G, Cuartero J, Pintilie M, Kamel-Reid S, Murphy J, Mackay H, Clarke B, Fyles A, Milosevic M.

Clin Oncol (R Coll Radiol). 2018 Apr;30(4):254-261. doi: 10.1016/j.clon.2018.01.011. Epub 2018 Feb 12.

PMID:
29449057
17.

Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy.

Spiegel JY, McNamara C, Kennedy JA, Panzarella T, Arruda A, Stockley T, Sukhai M, Thomas M, Bartoszko J, Ho J, Siddiq N, Maze D, Schimmer A, Schuh A, Sibai H, Yee K, Claudio J, Devlin R, Minden MD, Kamel-Reid S, Gupta V.

Blood Adv. 2017 Sep 8;1(20):1729-1738. doi: 10.1182/bloodadvances.2017009530. eCollection 2017 Sep 12.

18.

Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients.

Capoluongo E, Ellison G, López-Guerrero JA, Penault-Llorca F, Ligtenberg MJL, Banerjee S, Singer C, Friedman E, Markiefka B, Schirmacher P, Büttner R, van Asperen CJ, Ray-Coquard I, Endris V, Kamel-Reid S, Percival N, Bryce J, Röthlisberger B, Soong R, de Castro DG.

Semin Oncol. 2017 Jun;44(3):187-197. doi: 10.1053/j.seminoncol.2017.08.004. Epub 2017 Sep 15. Review.

19.

Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR, and KRAS Testing.

Kim AS, Bartley AN, Bridge JA, Kamel-Reid S, Lazar AJ, Lindeman NI, Long TA, Merker JD, Rai AJ, Rimm DL, Rothberg PG, Vasalos P, Moncur JT.

JAMA Oncol. 2018 Jun 1;4(6):838-841. doi: 10.1001/jamaoncol.2017.4021.

20.

Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer.

Pezo RC, Chen TW, Berman HK, Mulligan AM, Razak AA, Siu LL, Cescon DW, Amir E, Elser C, Warr DG, Sridhar SS, Yu C, Wang L, Stockley TL, Kamel-Reid S, Bedard PL.

Breast Cancer Res Treat. 2018 Feb;168(1):159-168. doi: 10.1007/s10549-017-4580-2. Epub 2017 Nov 24.

21.

Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma.

Lheureux S, Butler MO, Clarke B, Cristea MC, Martin LP, Tonkin K, Fleming GF, Tinker AV, Hirte HW, Tsoref D, Mackay H, Dhani NC, Ghatage P, Weberpals J, Welch S, Pham NA, Motta V, Sotov V, Wang L, Karakasis K, Udagani S, Kamel-Reid S, Streicher HZ, Shaw P, Oza AM.

JAMA Oncol. 2018 Jul 12;4(7):e173776. doi: 10.1001/jamaoncol.2017.3776. Epub 2018 Jul 12.

22.

Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience.

Chiu JW, Krzyzanowska MK, Serra S, Knox JJ, Dhani NC, Mackay H, Hedley D, Moore M, Liu G, Burkes RL, Brezden-Masley C, Roehrl MH, Craddock KJ, Tsao MS, Zhang T, Yu C, Kamel-Reid S, Siu LL, Bedard PL, Chen EX.

Clin Colorectal Cancer. 2018 Mar;17(1):73-79. doi: 10.1016/j.clcc.2017.10.010. Epub 2017 Oct 23.

PMID:
29128266
23.

Clinical utility of multigene profiling assays in early-stage breast cancer.

Chang MC, Souter LH, Kamel-Reid S, Rutherford M, Bedard P, Trudeau M, Hart J, Eisen A; Molecular Oncology Advisory Committee.

Curr Oncol. 2017 Oct;24(5):e403-e422. doi: 10.3747/co.24.3595. Epub 2017 Oct 25.

24.

T cell clonality assessment: past, present and future.

Mahe E, Pugh T, Kamel-Reid S.

J Clin Pathol. 2018 Mar;71(3):195-200. doi: 10.1136/jclinpath-2017-204761. Epub 2017 Oct 21. Review. Erratum in: J Clin Pathol. 2018 Jul;71(7):660.

25.

A Window Into Clinical Next-Generation Sequencing-Based Oncology Testing Practices.

Nagarajan R, Bartley AN, Bridge JA, Jennings LJ, Kamel-Reid S, Kim A, Lazar AJ, Lindeman NI, Moncur J, Rai AJ, Routbort MJ, Vasalos P, Merker JD.

Arch Pathol Lab Med. 2017 Dec;141(12):1679-1685. doi: 10.5858/arpa.2016-0542-CP. Epub 2017 Oct 13.

PMID:
29028368
26.

Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma.

Lewin J, Garg S, Lau BY, Dickson BC, Traub F, Gokgoz N, Griffin AM, Ferguson PC, Andrulis IL, Sim HW, Kamel-Reid S, Stockley TL, Siu LL, Wunder JS, Razak ARA.

Int J Cancer. 2018 Jan 1;142(1):57-65. doi: 10.1002/ijc.31039. Epub 2017 Oct 9.

27.

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results.

Hughes TP, Leber B, Cervantes F, Spector N, Pasquini R, Clementino NCD, Schwarer AP, Dorlhiac-Llacer PE, Mahon FX, Rea D, Guerci-Bresler A, Kamel-Reid S, Bendit I, Acharya S, Glynos T, Dalal D, Branford S, Lipton JH.

Leukemia. 2017 Nov;31(11):2529-2531. doi: 10.1038/leu.2017.247. Epub 2017 Aug 3. No abstract available.

28.

Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).

Labbé C, Cabanero M, Korpanty GJ, Tomasini P, Doherty MK, Mascaux C, Jao K, Pitcher B, Wang R, Pintilie M, Leighl NB, Feld R, Liu G, Bradbury PA, Kamel-Reid S, Tsao MS, Shepherd FA.

Lung Cancer. 2017 Sep;111:23-29. doi: 10.1016/j.lungcan.2017.06.014. Epub 2017 Jun 24.

PMID:
28838393
29.

Improving validation methods for molecular diagnostics: application of Bland-Altman, Deming and simple linear regression analyses in assay comparison and evaluation for next-generation sequencing.

Misyura M, Sukhai MA, Kulasignam V, Zhang T, Kamel-Reid S, Stockley TL.

J Clin Pathol. 2018 Feb;71(2):117-124. doi: 10.1136/jclinpath-2017-204520. Epub 2017 Jul 26.

30.

Uncommon EGFR mutations in advanced non-small cell lung cancer.

O'Kane GM, Bradbury PA, Feld R, Leighl NB, Liu G, Pisters KM, Kamel-Reid S, Tsao MS, Shepherd FA.

Lung Cancer. 2017 Jul;109:137-144. doi: 10.1016/j.lungcan.2017.04.016. Epub 2017 Apr 27. Review.

PMID:
28577943
31.

Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies.

Thomas M, Sukhai MA, Zhang T, Dolatshahi R, Harbi D, Garg S, Misyura M, Pugh T, Stockley TL, Kamel-Reid S.

Arch Pathol Lab Med. 2017 Jun;141(6):759-775. doi: 10.5858/arpa.2016-0547-RA. Epub 2017 Mar 9.

PMID:
28557600
32.

Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates.

Kis O, Kaedbey R, Chow S, Danesh A, Dowar M, Li T, Li Z, Liu J, Mansour M, Masih-Khan E, Zhang T, Bratman SV, Oza AM, Kamel-Reid S, Trudel S, Pugh TJ.

Nat Commun. 2017 May 11;8:15086. doi: 10.1038/ncomms15086.

33.

Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective.

Cabanero M, Sangha R, Sheffield BS, Sukhai M, Pakkal M, Kamel-Reid S, Karsan A, Ionescu D, Juergens RA, Butts C, Tsao MS.

Curr Oncol. 2017 Apr;24(2):111-119. doi: 10.3747/co.24.3524. Epub 2017 Apr 27. Review.

34.

Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario.

Lim C, Sekhon HS, Cutz JC, Hwang DM, Kamel-Reid S, Carter RF, Santos GDC, Waddell T, Binnie M, Patel M, Paul N, Chung T, Brade A, El-Maraghi R, Sit C, Tsao MS, Leighl NB.

Curr Oncol. 2017 Apr;24(2):103-110. doi: 10.3747/co.24.3495. Epub 2017 Apr 27.

35.

Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.

Malapelle U, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R, Savic S, Bihl M, Bubendorf L, Salto-Tellez M, de Biase D, Tallini G, Hwang DH, Sholl LM, Luthra R, Weynand B, Vander Borght S, Missiaglia E, Bongiovanni M, Stieber D, Vielh P, Schmitt F, Rappa A, Barberis M, Pepe F, Pisapia P, Serra N, Vigliar E, Bellevicine C, Fassan M, Rugge M, de Andrea CE, Lozano MD, Basolo F, Fontanini G, Nikiforov YE, Kamel-Reid S, da Cunha Santos G, Nikiforova MN, Roy-Chowdhuri S, Troncone G; Molecular Cytopathology Meeting Group.

Cancer Cytopathol. 2017 Aug;125(8):615-626. doi: 10.1002/cncy.21868. Epub 2017 May 5.

36.

Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer.

Doherty MK, Korpanty GJ, Tomasini P, Alizadeh M, Jao K, Labbé C, Mascaux CM, Martin P, Kamel-Reid S, Tsao MS, Pintilie M, Liu G, Bradbury PA, Feld R, Leighl NB, Chung C, Shepherd FA.

Radiother Oncol. 2017 May;123(2):195-202. doi: 10.1016/j.radonc.2017.03.007. Epub 2017 Mar 28.

PMID:
28363487
37.

Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.

Jennings LJ, Arcila ME, Corless C, Kamel-Reid S, Lubin IM, Pfeifer J, Temple-Smolkin RL, Voelkerding KV, Nikiforova MN.

J Mol Diagn. 2017 May;19(3):341-365. doi: 10.1016/j.jmoldx.2017.01.011. Epub 2017 Mar 21. Review.

PMID:
28341590
38.

Use of cytological samples of metastatic melanoma for ancillary studies.

Ko HM, Saieg MA, da Cunha Santos G, Kamel-Reid S, Boerner SL, Geddie WR.

Cytopathology. 2017 Jun;28(3):221-227. doi: 10.1111/cyt.12419. Epub 2017 Feb 20.

PMID:
28217853
39.

Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).

Spreafico A, Oza AM, Clarke BA, Mackay HJ, Shaw P, Butler M, Dhani NC, Lheureux S, Wilson MK, Welch S, Zhang T, Yu C, Stockley T, Siu LL, Kamel-Reid S, Bedard PL.

Gynecol Oncol. 2017 Feb;144(2):250-255. doi: 10.1016/j.ygyno.2016.12.002. Epub 2017 Jan 3.

PMID:
28062115
40.

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.

Stockley TL, Oza AM, Berman HK, Leighl NB, Knox JJ, Shepherd FA, Chen EX, Krzyzanowska MK, Dhani N, Joshua AM, Tsao MS, Serra S, Clarke B, Roehrl MH, Zhang T, Sukhai MA, Califaretti N, Trinkaus M, Shaw P, van der Kwast T, Wang L, Virtanen C, Kim RH, Razak AR, Hansen AR, Yu C, Pugh TJ, Kamel-Reid S, Siu LL, Bedard PL.

Genome Med. 2016 Oct 25;8(1):109.

41.

Comparison of Next-Generation Sequencing Panels and Platforms for Detection and Verification of Somatic Tumor Variants for Clinical Diagnostics.

Misyura M, Zhang T, Sukhai MA, Thomas M, Garg S, Kamel-Reid S, Stockley TL.

J Mol Diagn. 2016 Nov;18(6):842-850. doi: 10.1016/j.jmoldx.2016.06.004.

42.

Laboratory Investigation of Myeloproliferative Neoplasms (MPNs):  Recommendations of the Canadian Mpn Group.

Busque L, Porwit A, Day R, Olney HJ, Leber B, Éthier V, Sirhan S, Foltz L, Prchal J, Kamel-Reid S, Karsan A, Gupta V.

Am J Clin Pathol. 2016 Oct;146(4):408-22. doi: 10.1093/ajcp/aqw131. Review.

PMID:
27686169
43.

The Use of Targeted Therapies for Precision Medicine in Oncology.

White Al-Habeeb N, Kulasingam V, Diamandis EP, Yousef GM, Tsongalis GJ, Vermeulen L, Zhu Z, Kamel-Reid S.

Clin Chem. 2016 Dec;62(12):1556-1564. Epub 2016 Sep 27. No abstract available.

44.

Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer.

Aung KL, Stockley TL, Serra S, Kamel-Reid S, Bedard PL, Siu LL.

Cold Spring Harb Mol Case Stud. 2016 Sep;2(5):a001016. doi: 10.1101/mcs.a001016.

45.

Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBF-AML) - a single center analysis.

Deotare U, Shaheen M, Brandwein JM, Pitcher B, Kamel-Reid S, Yee KWL, Schimmer A, Minden MD, Gupta V, Schuh AC.

Hematol Oncol. 2017 Dec;35(4):810-813. doi: 10.1002/hon.2341. Epub 2016 Sep 6.

PMID:
27597292
46.

Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.

Melosky B, Agulnik J, Albadine R, Banerji S, Bebb DG, Bethune D, Blais N, Butts C, Cheema P, Cheung P, Cohen V, Deschenes J, Ionescu DN, Juergens R, Kamel-Reid S, Laurie SA, Liu G, Morzycki W, Tsao MS, Xu Z, Hirsh V.

Curr Oncol. 2016 Jun;23(3):196-200. doi: 10.3747/co.23.3120. Epub 2016 Jun 9.

47.

A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer.

Sacher AG, Le LW, Lara-Guerra H, Waddell TK, Sakashita S, Chen Z, Kim L, Zhang T, Kamel-Reid S, Salvarrey A, Darling G, Yasufuku K, Keshavjee S, de Perrot M, Shepherd FA, Liu G, Tsao MS, Leighl NB.

Oncotarget. 2016 May 3;7(18):25632-9. doi: 10.18632/oncotarget.8350.

48.

Extracorporeal photopheresis in solid organ transplant-associated acute graft-versus-host disease.

Houston BL, Yan M, Tinckam K, Kamel-Reid S, Chang H, Kuo KH, Tsien C, Seftel MD, Avitzur Y, Grant D, Cserti-Gazdewich CM.

Transfusion. 2016 Apr;56(4):962-9. doi: 10.1111/trf.13467. Epub 2016 Feb 18.

PMID:
26892365
49.

Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients.

Martin P, Shiau CJ, Pasic M, Tsao M, Kamel-Reid S, Lin S, Tudor R, Cheng S, Higgins B, Burkes R, Ng M, Arif S, Ellis PM, Hubay S, Kuruvilla S, Laurie SA, Li J, Hwang D, Lau A, Shepherd FA, Le LW, Leighl NB.

Br J Cancer. 2016 Mar 15;114(6):616-22. doi: 10.1038/bjc.2016.22. Epub 2016 Feb 18.

50.

A proposal for cellularity assessment for EGFR mutational analysis with a correlation with DNA yield and evaluation of the number of sections obtained from cell blocks for immunohistochemistry in non-small cell lung carcinoma.

da Cunha Santos G, Wyeth T, Reid A, Saieg MA, Pitcher B, Pintilie M, Kamel-Reid S, Tsao MS.

J Clin Pathol. 2016 Jul;69(7):607-11. doi: 10.1136/jclinpath-2015-203437. Epub 2016 Jan 5.

PMID:
26733659

Supplemental Content

Loading ...
Support Center